Therapeutic alternatives are limited for aggressive and recurrent meningiomas. Hyperactivation of the mTOR pathway and robust SSTR2A receptor expression has been demonstrated in meningiomas. Based on the authors' preclinical studies that assessed the additive antiproliferative effect of the combination of everolimus and octreotide on meningiomas, Graillon and colleagues initiated a clinical trial using the combination of everolimus and octreotide in aggressive meningiomas not amenable to any form of surgery/radiotherapy. The combination therap. was well-tolerated and resulted in a decline in tumor growth rate, suggesting that the combination of everolimus and octreotide could be considered an option for meningiomas.

Ovulation is the primary nonhereditary risk factor for ovarian cancer, yet the median age of diagnosis is 63 years old. To explore this timing disparity, McCloskey and colleagues investigated the effects of aging on both mouse and human ovaries and find that fibrosis develops with age in both species. Ovarian fibrosis correlated...

You do not currently have access to this content.